Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 92

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 2
Chunk 92
---
,198)(43)%Indirect costs:Personnel-related (including stock compensation)1,492,248 1,482,597 9,651 1 %Outside services (including consulting)19,287 2,878 16,409 570 %Facilities-related (including depreciation)18,198 23,405 (5,207)(22)%Other indirect R&D costs41,250 51,916 (10,666)(21)%Contra R&D expenses(448,392)(259,264)(189,128)73 %Total indirect R&D costs1,122,591 1,301,532 (178,941)(14)%Total R&D expenses$2,297,381 $3,353,520 $(1,056,139)(31)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (2) below. 2.These contra R&D expenses were recognized as follows for the three months ended March 31, 2025 and 2024: (a) Ovaprene, $0.5 million, and $0, respectively; (b) other advanced clinical stage programs, $0.5 million and $0 respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0.1 million and $0.2 million, respectively; and (d) preclinical stage programs, $1.6 million and $2.4 million, respectively.

The decrease of approximately $1.1 million in R&D expenses for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024 was primarily attributable to decreases in (i) manufacturing costs related to Ovaprene, (ii) costs related to development activities for Sildenafil Cream, and (iii) costs related to development activities for our preclinical stage programs. These decreases were partially offset by increases in costs related to our Phase 1 and Phase 1-ready clinical stage programs. Contra-R&D expenses for the three months ended March 31, 2025 and 2024 primarily offset direct program costs for DARE-LARC1, one of our preclinical stage programs. 

Royalty expenses

Royalty expenses for the